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Abstract
This chapter is intended to discuss the available oral anticoagulants,  
including vitamin K antagonists and the Direct Oral Anticoagulants such as dabi-
gatran, apixaban, rivaroxaban, and edoxaban. It will review their basic pharmacol-
ogy, pharmacokinetics, pharmacodynamics, dosage forms, clinical indications, 
and place in therapy. Finally, this chapter will also discuss the currently available 
reversal agents.
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1. Introduction
Thromboembolic diseases are a leading source of morbidity and death in the 
United States. Thrombosis can happen in either the arteries or the veins. Acute 
myocardial infarction (MI), ischemic stroke, and limb gangrene are all caused by 
arterial thrombosis. Deep vein thrombosis (DVT), which can cause post-thrombotic 
syndrome, and pulmonary embolism (PE), which can be fatal or cause thrombo-
embolic pulmonary hypertension, are both examples of venous thromboembolism 
(VTE). Arterial thrombosis is usually managed using antiplatelet therapy. On the 
other hand, VTE episodes are typically managed using anticoagulant therapy [1].
Anticoagulant drugs are the mainstay of therapy for many thrombotic disorders. 
The selection of one agent over the other is usually guided by balancing the risks 
versus the benefits of these anticoagulants. Also, it requires deep knowledge and 
understanding of the clinical pharmacology, efficacy, safety, and clinical outcomes 
for each of these anticoagulants.
Historically. Jay McLean and William Henry Howell discovered heparin a 
century ago, in 1914. However, it was first used in clinical practice in the 1940s. 
It’s given subcutaneously or intravenously, and it binds to antithrombin. This will 
improve its capacity to inactivate several clotting factors such as thrombin, factor 
Xa, and factor IXa [2]. Later on, several oral and parenteral antithrombotic agents 
are used to prevent and treat thrombotic episodes. In 1940, Karl Link and colleagues 
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discovered warfarin which is a vitamin-k antagonist. Warfarin was first marketed as 
a rodenticide. Later on, it was adopted for therapeutic usage as an anticoagulant [3].
In 2003, the discovery of ximelagatran showed that a particular oral throm-
bin inhibitor might be safe and effective in a range of thrombotic diseases, 
paving the way for introducing a new class of anticoagulants [4]. Following 
these advancements, a major millstone was declared in the field of anticoagula-
tion. Several direct oral anticoagulants (DOACs) targeting factors Xa and II 
were introduced from 2007 to 2014. According to several landmark randomized 
studies, they were shown to be equally safe and efficacious as warfarin in pre-
venting and treating venous thromboembolism and stroke prevention in atrial 
fibrillation. These advancements led to an enormous change in the landscape of 
managing thrombotic events [5].
This chapter is intended to review the currently available oral anticoagulants, 
including vitamin K antagonists (VKA), such as warfarin, and the (DOACs) such 
as dabigatran, apixaban, rivaroxaban, and edoxaban. In addition, it will discuss 
periprocedural management of anticoagulants, reversal modalities and highlight 
the major future advancements in the field of anticoagulation.
2. Vitamin K Antagonists
Warfarin is a vitamin K antagonist that was approved by the US Food and Drug 
Authority (FDA) in 1954 for stroke prevention. It is approved in many other indica-
tions such as managing and preventing VTE. Until recently, it was the only oral 
agent approved for these indications. However, more oral anticoagulants have been 
approved that possess more advantages and better pharmacokinetic properties. 
However, warfarin still a widely used medication to prevent blood clotting disor-
ders. Warfarin administration remains a challenge despite being used for more than 
60 years. Warfarin has a narrow therapeutic index and monitored regularly using 
international normalized ratio (INR). Duo to it inter and intra individual variation 
in response and multiple drug and food interactions, warfarin was replaced as a first 
line anticoagulant agent [6].
2.1 Mechanism of action
Warfarin exerts it anticoagulant effect by interfering with vitamin K epoxide 
reductase in the liver which serve as a cofactor for the carboxylation of glutamate 
to γ-carboxyglutamates. This process leads to the inhibition of vitamin K–depen-
dent γ-carboxylation of factors II, VII, IX, and X. However, Vitamin K antagonist 
does not inhibit the existing γ-carboxyglutamates that can lead to delay in its 
anticoagulant effect [6].
2.2 Pharmacology
Warfarin consists of a racemic mixture of S-warfarin and R-warfarin, in which 
the S- form being more active. It has high bioavailability with rapid absorption from 
the gastrointestinal tract. After drug administration, warfarin reaches maximum 
concentration within 90 mins. Warfarin is highly albumin bound with a half-life of 
36–42 hours. Warfarin is metabolized mainly in the liver through the cytochrome 
P450 (CYP) enzymes. However, the two isomers and metabolized through a 
different pathway in the liver. CYP2C9 is associated with the metabolism of the 
more potent S-warfarin whereas R-warfarin mainly metabolized by CYP1A2 and 
CYP3A4 [6].
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2.3 Indication and dosing
Warfarin has multiple indications including venous thrombosis, prosthetic heart 
valves and more commonly arterial fibrillation. Usually, the starting dose for war-
farin is 5–10 mg daily. However, lower doses can be initiated for patients at high risk 
of bleeding. Patients with known genetic polymorphism in CYP2C9 or VKORC1 can 
be more sensitive to warfarin. Also, elderly patients, patients with chronic kidney 
disease or patients on other medications that can cause bleeding can be initiated at 
a lower dose and up titrated to INR goal. Duo to its delayed antithrombotic effect, 
patients with established clot or high risk for thrombosis are bridged with a fast-act-
ing parenteral anticoagulant. Commonly, heparin or enoxaparin are given concomi-
tantly with warfarin until INR is at goal for 2 consecutive days with a minimum of 
5 days on parenteral anticoagulant [6].
2.4 Monitoring
Warfarin is a drug known for its narrow therapeutic index as well as having 
multiple drug and food interactions. Therefore, continuous monitoring is important 
to ensure anticoagulation efficacy is achieved and severe side effects are avoided. 
INR is calculated from prothrombin time which is a test that measures how long a 
clot is formed in a blood sample is performed when patients are on warfarin. Mostly, 
warfarin is given to achieve an INR goal of 2–3. However, patients with a mechanical 
mitral valves or mechanical aortic valve replacement with Starr-Edwards or disc 
valves have a higher INR target of 2.5–3.5 duo to higher thromboembolic risk [6].
2.5 Side effects
One of the major risks associated with using warfarin is bleeding and the severity 
of bleeding can vary. Majority of bleeding side effect is seen when INR suprathera-
peutic. Therefore, INR monitored and maintained at target is essential to minimize 
bleeding risk. There are several approaches to manage a supratherapeutic INR and 
the choice usually depends on the present or absent of bleeding, severity of bleeding 
and magnitude in which INR increased. Skin necrosis is a rare complication associ-
ated with warfarin administration in patients with protein C or S deficiency [6].
2.6 Drug interaction
Warfarin can interact with large number of medications. Drugs can cause 
pharmacodynamic or pharmacokinetic interaction with warfarin. Pharmacokinetic 
interactions involve medications that inhibit or induce CYP2C9, CYP1A2 or 
CYP3A4 which can alter warfarin concentration. Inhibitors of the CYP enzymes 
can interfere with warfarin metabolism that leads to higher warfarin concentration. 
However, CYP enzyme inducers can increase warfarin removal, therefore, decrease 
its effect. Pharmacodynamic interaction can occur when warfarin given with other 
anticoagulants, antiplatelet, non-steroidal anti-inflammatory drugs, or serotonin 
Reuptake Inhibitors. In which, these drugs can increase risk of bleeding [6].
3. Direct Oral Anticoagulants
Direct oral anticoagulants (DOACs) have been introduced to the market initially 
in 2010 as a potential alternative for warfarin. They possess many advantages 
over warfarin that placed them as the first-line anticoagulant option for many 
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indications. These agents include apixaban, rivaroxaban, edoxaban, and dabiga-
tran. All of these agents do not require regular monitoring of their anticoagulant 
effect and they achieve the target anticoagulation level shortly given their fast onset 
of action compared to warfarin. These significant advantages placed these agents as 
the preferred anticoagulant option by patients and clinicians [7].
3.1 Mechanism of action
Factor Xa is a crucial coagulation factor in the coagulation cascade that leads 
to the formation of thrombin and clot generation. Apixaban, rivaroxaban, and 
edoxaban, bind directly and reversibly to factor Xa and inhibit its action leading to a 
strong anticoagulation activity. On the other side, dabigatran inhibits directly factor 
IIa (thrombin), leading to the prevention of clot formation [8].
3.2 Pharmacology
Apixaban binds directly to factor Xa when free and when thrombin bound. It has 
a bioavailability of approximately 50% and reaches a plasma peak in about 2 hours 
with maximum plasma concentration in about 3 to 4 hours. It has a half-life of 
approximately 12 hours after oral administration necessitating twice-daily dosing. 
It is metabolized mainly by CYP3A4 and eliminated in both urine and feces. Renal 
elimination accounts for 27% of total clearance. Apixaban has no interaction with 
food but is a substrate of P-glycoprotein (P-gp) and CYP3A4 requiring vigilant 
review of concurrent medications for possible drug–drug interactions [9].
Dabigatran is the active form of the prodrug dabigatran etexilate, which binds 
thrombin directly and competitively inhibiting its activity. The approximate 
bioavailability of dabigatran after oral administration is 3–7%, with peak plasma 
concentration achievement within 2 hours. The bioavailability increased to 75% 
after the pellets were taken without the capsule. Therefore, the capsules should not 
be broken, chewed, or opened before administration. The half-life of dabigatran is 
approximately 12–17 hours, necessitating twice-daily dosing. Dabigatran is mainly 
eliminated in the urine with a renal clearance of roughly 80%. It is a substrate of 
P-gp and therefore, it carries a risk for drug–drug interactions [9].
Edoxaban binds selectively to factor Xa and inhibits its action without the need 
for a cofactor (i.e., antithrombin III). It has a bioavailability of approximately 62% 
and reaches a peak plasma concentration in about 1 to 2 hours. It has a half-life 
of approximately 10–14 hours, and 50% of the total clearance is through urine. 
Therefore, edoxaban blood levels are increased or decreased in patients with poor or 
good renal function. Edoxaban is a substrate for P-gp and CYP3A4, increasing the 
risk for drug–drug interactions [9].
Rivaroxaban is a selective inhibitor of factor Xa with no requirement for a 
cofactor (i.e., antithrombin III) with no direct effect on platelet aggregation. It 
has a very high bioavailability following oral administration of 2.5 mg and 10 mg 
doses reaching 80–100%. Administration with food increases the bioavailability of 
rivaroxaban. Therefore, it should be taken with food. Peak plasma concentration is 
achieved in about 2 to 4 hours. It has a renal clearance of up to 30%. Rivaroxaban 
is a substrate for P-gp increasing the risk of drug–drug interactions [9]. Table 1 
summarizes the pharmacological properties of DOACs.
3.3 Indications and dosing
DOACs are currently used in different indications, including reducing the 
incidence of stroke in patients with NVAF, treatment of acute VTE, and reducing 
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the risk of recurrent VTE. Finally, apixaban, rivaroxaban, and dabigatran have 
been approved by US FDA and European Medical Agency (EMA) for thrombo-
prophylaxis post orthopedic surgeries (i.e., knee and hip replacements). Apixaban 
and rivaroxaban are approved for post-knee and hip replacement surgeries, and 
dabigatran is only approved for post-hip replacement surgery. In addition, rivaroxa-
ban is also approved for VTE prophylaxis in acutely ill medical patients at risk for 
thromboembolic complications, not at high risk of bleeding [9]. Table 2 illustrates 
the usual dosing recommendations for the various indications.
3.4 Monitoring
DOACs possess the advantage of having predictable pharmacokinetic and phar-
macodynamic properties making their regular monitoring of blood levels or coagu-
lation factors not necessary. This provides a great advantage and more convenience 
to patients than the traditional anticoagulant warfarin. Currently, there are no 
validated and clinically feasible tests to measure the anticoagulant effect of DOACs 
on daily basis. Besides, routine monitoring of kidney function is necessary to 
ensure appropriate clearance of DOACs as all of them have varying degrees of renal 
elimination. This becomes of high importance when dealing with end-stage renal 
disease patients or patients on hemodialysis. Monitoring hepatic function every 6 to 
12 months is recommended as all DOACs except dabigatran are metabolized by the 
liver. Regular follow-up on patient adherence is also encouraged to ensure the safety 
and efficacy of the anticoagulation given their short duration of action [9].
3.5 Side effects
As with all anticoagulants, the main severe and concerning side effect is bleed-
ing. Careful watching of signs and symptoms of bleeding and proper patient 
education on identifying them is crucial. Dyspepsia is another reported side effect 
more linked to dabigatran. Taking dabigatran with food should help with minimiz-
ing dyspepsia as the body tolerates the medication with time [10].
3.6 Choosing an anticoagulant agent
Warfarin could be an appealing anticoagulant option in many cases. For example, 
it could be an adequate option to be sued in patients with an estimated creatinine 
Apixaban Dabigatran Edoxaban Rivaroxaban
Mechanism of action Factor Xa Thrombin Factor Xa Factor Xa
Pro-drug No Yes No No
Bioavailability 50% 3%-7% 62% 66%-80%
Time to peak 2 hours 2 hours 1-2 hours 2-4 hours
Half-life 12 hours 12-17 hours 12-14 hours 9-13 hours
Protein binding 87% 35% 55% 90%
Renal elimination 27% 80% 50% 30%
Substrate of CYP3A4 Yes No Yes Yes
Substrate of P-gp Yes Yes Yes Yes
Dialyzable No Yes No No
Table 1. 
Pharmacological properties of DOACs.
Thrombectomy - Recent Advances in Ischaemic Damage Treatment
6
clearance (CrCl) of less than 30 mL/min as those individuals were excluded from 
many clinical trials that compared warfarin to the DOACs. Also, it could be used 
in patients with poor medication adherence. This is mainly because many of the 
currently available DOACs are dosed to be taken twice daily. This could affect patient 
adherence. In addition, the presence of laboratory assessment modalities like the 
INR can identify poor medication adherence. Despite the long list of interacting 
medications with warfarin, the use of warfarin could be preferred as dose adjustments 
based on INR monitoring can facilitate titration of the anticoagulant response. Warfarin 
remains the least expensive anticoagulant currently available. This could make it a 
reasonable option for individuals who cannot afford the more costly options [11].
DOACs are considered the first line option in many indications given their 
predicted pharmacokinetics and pharmacodynamics which minimizes the need for 
regular drug monitoring compared to warfarin. They are dosed either once daily 
Apixaban Dabigatran Edoxaban Rivaroxaban
Stroke prevention in nonvalvular atrial fibrillation (NVAF)
5 mg PO BID
2.5 mg PO BID if two of the 
following occurs:
• Age ≥ 80 years
• Scr ≥ 1.5 mg/dl
• Weight ≤ 60 kg




CrCl > 95 ml/
min
20 mg PO once daily
Treatment of acute venous thromboembolism (VTE)
10 mg PO BID for 7 days, then 5 
mg PO BID
Following 5-10 days 
of initial parenteral 
therapy: 150 mg 
PO BID
Following 5-10 
days of initial 
parenteral 
therapy:
• Weight > 60 kg: 
60 mg PO once 
daily
• Weight ≤ 60 kg: 
30 mg PO once 
daily
15 mg PO BID for 21 
days, then 20 mg PO 
once daily
Reduction in the risk of recurrent VTE
2.5 mg PO BID 150 mg PO BID Not approved 10 mg PO once daily
Post-knee/hip replacement DVT prophylaxis
2.5 mg PO BID 12-24 hours 
post-op
• Hip replacement duration: 
35 days
• Knee replacement duration: 
12 days
Hip replacement 
only: 110 mg PO 
1-4 hours post-
surgery, then 220 
mg PO once daily 
for 28-35 days
Not approved 10 mg PO once daily 
6-10 hours post-op
• Hip replacement 
duration: 35 days
• Knee replacement 
duration: 12 days
VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications, not at high 
risk of bleeding
Not approved Not approved Not approved 10 mg PO once 
daily in the hospital 
and after hospital 
discharge for a total 
duration of 31-39 
days
Table 2. 
DOACs approved indications and recommended doses for normal kidney patients.
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or twice daily and do not have significant drug-food interactions. Patients with 
various degrees of renal impairment (i.e. CrCL <30 ml/min) were excluded from 
the DOACs’ pivotal trials, therefore their use in this certain population is debatable. 
However, apixaban, for example has good pharmacokinetic data supporting its 
use in hemodialysis (HD) patients as it has very low renal clearance that accounts 
for only 25%. Currently, apixaban is recommended for stroke prevention in atrial 
fibrillation patients with end stage renal disease (ESRD) on HD. On the other hand, 
patients with poor compliance may benefit more from being on warfarin rather 
than DOACs as the effect of warfarin stays longer than DOACs. If a patient misses 
one dose of warfarin, the INR would still be in the therapeutic range for one or 
more days. Finally, the need to monitor kidney function with DOACs still exists and 
crucial to assess the need for renal dose adjustments [12, 13].
3.7 Periprocedural management of anticoagulation
Management of anticoagulation before and after surgeries such as thrombectomy is 
very crucial safety step to ensure safe and effective surgical interventions with minimal 
chances for bleedings. The appropriate knowledge of anticoagulants pharmacokinetics 
properties and the degree of bleeding risk of the procedure are two essential factors to 
formulate an appropriate periprocedural anticoagulation plan. Special considerations 





Minimal • Omit anticoagulant on the day of 
procedure
• No interruption needed
Low • Omit anticoagulant one day before 
the procedure
• Reinitiate anticoagulant one day after 
the procedure
• For individuals receiving dabigatran 
with CrCl 30 to 50 mL/min: omit two 
days before procedure.
• Assess thromboembolic risk:
• Low – moderate risk: interrupt 5 days 
before the procedure without parenteral 
anticoagulant bridging
• High risk: interrupt 5 days before the 
procedure with parenteral anticoagulant 
bridging
Moderate • Omit anticoagulant one day before 
the procedure
• Reinitiate anticoagulant one day after 
the procedure
• Assess thromboembolic risk:
• Low – moderate risk: interrupt 5 days 
before the procedure without parenteral 
anticoagulant bridging
• High risk: interrupt 5 days before the 
procedure with parenteral anticoagulant 
bridging
• Reinitiate warfarin postoperatively once 
hemostasis is attained
High • Omit anticoagulant two day before 
the procedure
• Reinitiate anticoagulant two day after 
the procedure
• For individuals receiving dabigatran 
with CrCl 30 to 50 mL/min: omit four 
days before procedure
• interrupt 5 days before the procedure with 
parenteral anticoagulant bridging
• Reinitiate warfarin postoperatively once 
hemostasis is attained
Table 3. 
Periprocedural management of anticoagulants.
Thrombectomy - Recent Advances in Ischaemic Damage Treatment
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In patients who are on a DOAC and going into a minimal risk procedure, 
omitting one dose of the anticoagulant on the day of the procedure is sufficient. 
However, in low or moderate risk procedures, the anticoagulant should be omit-
ted for one day before the procedure and restart one day after the procedure. In 
high-risk procedures, omitting the DOAC agent two days before and after the 
procedure would reasonable. Table 3 summarizes the periprocedural management 
of anticoagulants.
On the other side, patients who are on warfarin and undergoing minimal risk 
procedures, interruption of anticoagulation is not necessary. However, in other low 
and moderate risk procedures, warfarin should be interrupted with mostly no need 
for bridging. In high risk, interruption of anticoagulation is needed with bridg-
ing. Discontinuation of warfarin should be done five days before the procedure. 
When bridging is required, starting enoxaparin three days before the procedure 
is reasonable with last dose being given 24 hours before the procedure. In patients 
with various degrees of renal impairments may require longer interruption periods 
as clearance of the anticoagulant may become delayed. Table 3 summarizes the 
periprocedural management of anticoagulants.
4. Reversal Agents
4.1 Warfarin reversal modalities
Holding or discontinuing warfarin as a solo strategy may be adequate in asymp-
tomatic patients with an elevated INR value and a low risk for bleeding. Certain 
patient may require further agents to be administered such as, Vitamin K (phy-
tonadione), Prothrombin Complex Concentrate (PCC), and Fresh frozen plasma 
(FFP) [15].
4.1.1 Vitamin K (Phytonadione)
Exogenous vitamin K level helps reestablishing the hepatic formation of vitamin 
K–dependent clotting factors. When exogenous vitamin K is given, it can continue 
to be reduced and converted to its active form, KH2, which results with functional 
clotting factors despite recent warfarin administration. Vitamin K dose and route of 
administration vary depends on the bleeding magnitude. It can be given as 2–5 mg 
PO/IV for minor bleeding events and 5–10 IV for major bleed. Although they are 
rare, anaphylactic reactions and temporary warfarin resistance have been reported 
with vitamin K use IV vitamin K normalizes the INR quicker than PO. It only takes 
8–12 hours with IV administration and might take up to 24–48 hours following oral 
administration [15].
4.1.2 Prothrombin Complex Concentrate (PCC)
Clotting factor replenishing, and it can enchase platelet activation. These 
clotting factors are 25-fold more concentrated than blood. Recombinant activated 
factor VII (FVIIa) (NovoSeven®) contains activated factor VII can directly activate 
thrombin generation by binding to tissue factor. PCC products are differentiated 
by the type of clotting factors they consist of. The 3-factor PCC consist of clotting 
factors II, IX, and X. The 4-factor PCC 4 consist of clotting factors II, IX, X, and 
VII (4PCC). Activated 4-factor PCC consist of II, IX, X, and VIIa. All PCC products 
have natural anticoagulants protein C and protein S. and all PCC products contain 
heparin, except Profilnine® (3-factor PCC)[15].
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PCC dosing is based on factor IX and activated versus non-activated pertains to 
factor VII. Normally each single-dose vial of PCC is mixed with 10–40 mL of sterile 
water. Fixed dose PCC for non-intracranial hemorrhagic (ICH) bleed is usually 
1000 units while in ICH, it is 1500–2000 units. The other modality to dose PCC 
is INR and weight driven dose. In patients with INR of 2 to less than 4, the dose is 
25 units/kg. In patients with INR of 4–6,, the dose is 35 units/kg. In patients with 
INR of more than 6, the dose is 50 units/kg. PCC dose might need to be rounded up 
or down to the nearest available vial size. The acceptable dose adjusting margin is 
institution dependent (usually 5–10%). Infusion related allergic reactions, heparin-
induced thrombocytopenia (with exception of Profilnine®) and low acceptable 
risk of thrombosis have been reported in patients receiving PCC therapy [15].
4.1.3 Fresh frozen plasma (FFP)
FFP is not a specific reversal agent. It contains all coagulation factors, includ-
ing II, VII, IX, and X in diluted inactive form. Moreover, it contains fibrinogen 
and platelet. There is no specific recommendation when it comes to FFP dosing, 
but usually it is given as 10–30 mL/kg (1-unit FFP has a volume of 250 mL). 
Transfusion reactions, volume overload, infection, and transfusion-related lung 
injury have been reported in patients receiving FFP therapy [15].
4.2 Direct thrombin inhibitors reversal agents
4.2.1 Idarucizumab
Idarucizumab is a humanized monoclonal antibody fragment that has been 
developed specifically to reverse the anticoagulation effect of dabigatran [9]. 
Idarucizumab is indicated for emergent surgery/urgent procedures In life-
threatening or uncontrolled bleeding. It is given as a total dose of 5 grams (two 
separate doses of 2.5 g diluted in 50 mL vials) intravenous infusion over 5 minutes. 
Idarucizumab carries a warning for inducing thromboembolic events. The throm-
botic rate in REVERSE-AD trial was 4.8% at 1 month. The risks of hypersensitiv-
ity and severe adverse reactions in patients with hereditary fructose intolerance 
are reported in the packaging insert due to sorbitol excipient. Among patients 
who received Idarucizumab, 5% or more experienced hypokalemia, pneumonia, 
pyrexia, and delirium [9].
4.2.2 Prothrombin Complex Concentrates (PCC)
Inconsistent data was reported regarding the efficacy of PCC in reversing 
dabigatran based on its laboratory abnormalities. When PCC is used, aPCC such as 
FEIBA may be preferred. The thrombin generation following PCC administration 
is dose dependent. Currently most guidelines recommend aPCC 50 units/kg to be 
given when an emergent reversal is needed for dabigatran. Because of the presence 
of activated clotting factors, and higher prothrombin and thrombin content in 
aPCC, the risk of thrombosis is expected to be higher with aPCC than with PCC [9].
4.3 Anti-Xa inhibitors reversal agents
4.3.1 Andexanet alfa
Andexanet alpha is a recombinant modified human “decoy” factor Xa protein, 
and it works through a competitive binding mechanism with high specificity to 
Thrombectomy - Recent Advances in Ischaemic Damage Treatment
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direct and indirect anti-Xa agents; to restore the activity of factor Xa and reverses 
the anticoagulant effect. In May 2018, the FDA approved Andexxa® for the reversal 
of apixaban and rivaroxaban in the setting of life-threatening or uncontrolled 
major bleeding. Later, the European Medicine Agency (EMA) gave it a ‘conditional 
authorization’ in 2019 using the trade name of (Ondexxya®)[9].
Andexanet alpha dosing is either 400 mg IV bolus followed by continuous IV 
infusion or 800 mg IV bolus followed by 960 mg continuous IV infusion, based 
on drug, dose, and timing. Treatment with the high dose would cost $49,500 for 
the drug alone. It is available as 100-mg dry powder vials. It needs to be reconsti-
tuted with 10 mL SWFI with typical dissolution time of 3 minutes. Most common 
reported issues related to andexanet alfa include flushing and fever which may be 
an infusion related side effect in study performed in healthy volunteers. Albeit 
the decoy mechanism of action of this drug, the most common side effects in 
patients with major bleeding events were thromboembolism including DVTs, 
myocardial infarction and ischemic stroke which was reported in 10% in the 
ANEXXA-4 trial.
4.3.2 Prothrombin Complex Concentrates (PCCs)
Variable data have been reported on the role of PCC in anti-Xa as potential 
reversal strategies. Multiple guidelines suggest using PCCs as alternative method 
to andexanet alfa. However, multiple reports demonstrated similar efficacy and 
safety profile for PCCs when used for major bleed induced by rivaroxaban, apixa-
ban, or edoxaban. Many clinicians may prefer PCCs over andexanet alfa based on 
the cost difference in addition to the lack of high-quality head-to-head compari-
sons. Dosing may have a range between 25 and 50 units/kg based on actual body 
weight [9].
5. Ongoing research on anticoagulant therapy
The anti-factor Xa inhibitors have achieved so many milestones and currently 
are recommended by most well-respected clinical guidelines. This mechanism of 
action is becoming so appealing for many manufacturers to design new agents 
that specifically target factor Xa. Darexaban and nokxaban are two new potential 
agents that may see the light soon and attain the guidelines recommendations 
for many clinical indications. They have still not been approved by neither the 
US FDA nor the EMA but their Phase II trials are promising with comparable 
safety and efficacy data to current approved DOACs. On the other side, cur-
rently approved DOACs are being tested for many other indications and we may 
see further utilization of these agents on a wider range of patient population. 
Drugs targeting other coagulation factors such as factor XI and XII are also being 
developed [16–19].
6. Conclusion
Several anticoagulant agents could be used to manage thrombotic events. 
However, it is essential to consider thrombectomy over anticoagulant therapy 
in acute settings. This is mainly due to the fact that limited data exist on the 
use of VKA or DOACs in the acute treatment of patients with ischemic stroke. 
Anticoagulants could be reserved as a secondary prevention strategy in many 
thrombotic disorders.
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